Vigilare Wealth Management acquired a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 6,430 shares of the exchange traded fund’s stock, valued at approximately $1,014,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Trek Financial LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 105.5% in the 3rd quarter. Trek Financial LLC now owns 80,717 shares of the exchange traded fund’s stock worth $12,727,000 after buying an additional 41,441 shares during the period. Bank Julius Baer & Co. Ltd Zurich grew its position in shares of SPDR S&P Biotech ETF by 6.4% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 29,480 shares of the exchange traded fund’s stock worth $4,648,000 after buying an additional 1,786 shares in the last quarter. Bell Investment Advisors Inc increased its stake in shares of SPDR S&P Biotech ETF by 268.8% during the third quarter. Bell Investment Advisors Inc now owns 343 shares of the exchange traded fund’s stock valued at $54,000 after buying an additional 250 shares during the period. Vise Technologies Inc. increased its stake in shares of SPDR S&P Biotech ETF by 29.2% during the third quarter. Vise Technologies Inc. now owns 2,066 shares of the exchange traded fund’s stock valued at $326,000 after buying an additional 467 shares during the period. Finally, Investment Partners LTD. raised its holdings in shares of SPDR S&P Biotech ETF by 102.1% in the third quarter. Investment Partners LTD. now owns 3,215 shares of the exchange traded fund’s stock valued at $507,000 after acquiring an additional 1,624 shares in the last quarter.
SPDR S&P Biotech ETF Price Performance
NYSEARCA:XBI opened at $155.98 on Monday. SPDR S&P Biotech ETF has a 1-year low of $106.30 and a 1-year high of $169.89. The company has a 50-day moving average of $156.60 and a 200 day moving average of $141.58. The firm has a market cap of $10.72 billion, a PE ratio of 11.47 and a beta of 0.83.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
